Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NewBridge Pharmaceuticals logo — A regional specialty company providing a one-stop-solution t...

NewBridge Pharmaceuticals

A regional specialty company providing a one-stop-solution to the MENA region for USFDA/EMA approved products

Founded 2010 United Arab Emirates United Arab Emirates 252 employees Series C Total: $60.00M Biotechnology, Medical Devices +1

General Information

Company Name NewBridge Pharmaceuticals
Founded Year 2010
Location United Arab Emirates United Arab Emirates
Employees 252
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with NewBridge Pharmaceuticals. To contact NewBridge Pharmaceuticals, visit nbpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NewBridge Pharmaceuticals compare?

A PDF of NewBridge Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NewBridge Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NewBridge Pharmaceuticals

NewBridge Pharmaceuticals is a regional specialty company based in the United Arab Emirates, specializing in providing a one-stop solution for USFDA/EMA approved products in the Middle East and Africa. Established in 2007, NewBridge aims to bridge the access gap and collaborate with pharmaceutical and biotech companies to in-license and commercialize innovative pharmaceutics, biologics, and other healthcare solutions in the region. The company's strategic focus areas include Oncology, Immunology, Neuroscience, Gastrointestinal & Nutrition. With a product portfolio addressing unmet medical needs, NewBridge has gained a substantial presence and facilitated patients' access to much-needed innovations. Its leadership team, experienced in the biopharmaceutical industry regionally and globally, has solidified NewBridge as a strategic pharmaceutical partner in the MENA region. NewBridge offers flexible partnership opportunities and best practices in commercial, regulatory, and medical affairs, focusing on quality performance and high standards of compliance. The company has secured a $48.00M Series C investment on 29 May 2013 from investors such as Burrill & Company, Elan Corporation, and Kuwait Life Sciences Company. This financial backing and life science network support NewBridge’s vision to create value through an innovative business approach and build successful alliances in the region. Its integrated strategy of regional expertise and strong global business network positions NewBridge as the preferred partner-of-choice for biopharmaceutical and healthcare companies seeking multi-country access in the Middle East and Africa.

Business keywords: pharmaceuticals, biologics, oncology, immunology, neuroscience, gastrointestinal, nutrition, healthcare solutions, MENA region, commercialization, FDA approval, EMA approval, partnerships, regional expertise, institutional investors

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $48.00M 3
Burrill & Company
Burrill & Company, Elan Corporation +1
29 May 2013
Series B $12.00M 2
Burrill & Company
Burrill & Company, Kuwait Life Sciences Company
20 Sep 2010

NewBridge Pharmaceuticals Alternatives & Competitors

View All Alternatives
NewBridge Pharmaceuticals vs
شركة سدير للأدوية
شركة سدير للأدوية Saudi Arabia

سنواصل رحلتنا لتحقيق رؤيتنا وسنكون مصدر إلهام للجميع في صناعة الأدوية.

346 employees
Biotechnology, Health Care
Compare NewBridge Pharmaceuticals vs شركة سدير للأدوية
NewBridge Pharmaceuticals vs
Takeda Oncology
Takeda Oncology United States

We aspire to cure cancer, with inspiration from patients and innovation from everywhere.

1621 employees
Biopharma, Biotechnology
Compare NewBridge Pharmaceuticals vs Takeda Oncology
NewBridge Pharmaceuticals vs
TRIDEM Pharma
TRIDEM Pharma France

A global outsourcing solution for pharmaceutical groups

485 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About NewBridge Pharmaceuticals

A regional specialty company providing a one-stop-solution to the MENA region for USFDA/EMA approved products
NewBridge Pharmaceuticals was founded in 2010.
NewBridge Pharmaceuticals is headquartered in United Arab Emirates.
NewBridge Pharmaceuticals operates in Biotechnology, Medical Devices and Pharmaceutical. Its work centres on pharmaceuticals, biologics, oncology and immunology.
NewBridge Pharmaceuticals has approximately 252 employees.
NewBridge Pharmaceuticals has completed 2 funding rounds, raising a total of $60.00M. The latest funding stage is Series C.
Top alternatives and competitors to NewBridge Pharmaceuticals include شركة سدير للأدوية, Takeda Oncology, TRIDEM Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NewBridge Pharmaceuticals and شركة سدير للأدوية are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NewBridge Pharmaceuticals, https://bouncewatch.com/company/newbridge-pharmaceuticals, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout